The Role of Salvage Second Autologous Hematopoietic Cell Transplantation in Relapsed Multiple Myeloma
Multiple myeloma (MM) is a malignant disorder of plasma cells primarily affecting elderly patients with a median age at diagnosis in the late 60s to early 70s [1]. It is the second most commonly diagnosed hematological neoplasm with an estimated incidence of 30,280 cases in 2017 and prevalence of 118,539 in 2014 [2]. With effective new agents now available including proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies, significant advances have been made in the treatment of MM. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - December 8, 2018 Category: Hematology Authors: Patrick Alan Hagen, Patrick Stiff Source Type: research

Human rhinovirus infections in hematopoietic cell transplant recipients: risk score for progression to lower respiratory tract infection
Human rhinovirus (HRV) is the most commonly detected respiratory virus following hematopoietic cell transplantation (HCT) in both the upper and lower respiratory tract [1,2]. Though rare, once virologically confirmed lower respiratory tract infection (LRTI) has developed, mortality rates due to HRV appear to be high (21% to 41%) and even similar to those seen with other respiratory viruses including influenza, respiratory syncytial virus (RSV), and parainfluenza viruses (PIVs) [3 –5]. Risk factors associated with LRTI in this population have been defined for RSV, PIVs, influenza, and human metapneumovirus (HMPV) [6&n...
Source: Biology of Blood and Marrow Transplantation - December 8, 2018 Category: Hematology Authors: Alpana Waghmare, Hu Xie, Jane Kuypers, Mohamed L. Sorror, Keith R. Jerome, Janet A. Englund, Michael Boeckh, Wendy M. Leisenring Source Type: research

Direct HLA Genetic Comparisons Identify Highly Matched Unrelated Donor/Recipient Pairs with Improved Transplant Outcome
Consistent with their role in immune recognition, HLA genes are the most polymorphic loci in the human genome. Within the HLA genes, the highest degree of genetic polymorphism is found within a few exons that encode the peptide and T cell receptor binding regions of the HLA proteins (also termed antigen recognition domains) [1]. For HLA class I proteins (HLA-A, -B, and -C), exons 2 and 3 encode the peptide binding site, while exon 2 encodes the peptide binding site for HLA class II proteins (HLA-DR, -DQ, and -DP). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - December 8, 2018 Category: Hematology Authors: Ibrahim Vazirabad, Saurabh Chhabra, James Nytes, Vatsal Mehra, Ravi K. Narra, Aniko Szabo, James H. Jerkins, Binod Dhakal, Parameswaran Hari, Matthew W. Anderson Source Type: research

Allogeneic hematopoietic stem cell transplantation, especially haploidentical HSCT, may improve long-term survival for high-risk pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) occurs in 3% –5% of patients with childhood ALL and is associated with dismal outcomes when treated with chemotherapy alone in the era of pre-tyrosine kinase inhibitors (TKIs) [1]. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is often recommended because it results in a lower relapse rate [1- 3]. Over the past decade, an imatinib-incorporating regimen has been reported to increase complete remission (CR) and has resulted in promising outcomes similar to that of allo-HSCT in pediatric patients with Ph+ALL [4-7]. (Source: Biology o...
Source: Biology of Blood and Marrow Transplantation - December 8, 2018 Category: Hematology Authors: Yu-juan Xue, Yi-fei Cheng, Ai-dong Lu, Yu Wang, Ying-xi Zuo, Chen-hua Yan, Jun Wu, Yu-qian Sun, Pan Suo, Yu-hong Chen, Huan Chen, Yue-ping Jia, Kai-yan Liu, Wei Han, Lan-ping Xu, Le-ping Zhang, Xiao-jun Huang Source Type: research

Analysis of Single Nucleotide Polymorphisms in the Gamma Block of the Major Histocompatibility Complex in Association with Clinical Outcomes of Hematopoietic Cell Transplantation: A CIBMTR Study
Human leukocyte antigen (HLA) mismatches have the strongest impact on clinical outcomes following unrelated hematopoietic cell transplantation (HCT).1,2 In addition, in otherwise genotypically HLA matched unrelated donor HCT; major histocompatibility complex (MHC) haplotype mismatches have been associated with higher risk of graft versus host disease (GVHD) and with lower risk of disease relapse.3 The MHC region spans approximately 3.8 megabases (Mb) of the short arm of chromosome 6 at 6p21.3 and includes over 269 loci. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - December 8, 2018 Category: Hematology Authors: Medhat Askar, David Sayer, Tao Wang, Michael Haagenson, Stephen R. Spellman, Stephanie J. Lee, Abeer Madbouly, Katharina Fleischhauer, Katharine C. Hsu, Michael R. Verneris, Dawn Thomas, Aiwen Zhang, Ronald M. Sobecks, Navneet S. Majhail, CIBMTR ® Immuno Source Type: research

Autologous Stem Cell Transplant for IgM Associated AL amyloidosis
Amyloidosis related to an IgM monoclonal protein is a rare entity accounting for approximately 5% of patients with immunoglobulin light chain (AL) amyloidosis [1,2]. Patients with IgM related AL amyloidosis tend to present with lower levels of serum free light chains, have less cardiac involvement and more neurological involvement compared to those with non-IgM related AL amyloidosis [1 –3]. Therapy is generally extrapolated form regimens used for non-IgM related AL amyloidosis. However given the lymphoplasmacytic nature of the clonal disorder in these patients, regimens used to treat lymphoplasmacytic lymphoma have ...
Source: Biology of Blood and Marrow Transplantation - December 7, 2018 Category: Hematology Authors: M Hasib Sidiqi, Francis K. Buadi, Angela Dispenzieri, Rahma Warsame, Martha Q. Lacy, David Dingli, Nelson Leung, Wilson I. Gonsalves, Prashant Kapoor, Taxiarchis V. Kourelis, William J. Hogan, Shaji K. Kumar, Morie A. Gertz Source Type: research

Reduced-toxicity myeloablative conditioning consisting of fludarabine/busulfan/low-dose TBI/G-CSF-combined cytarabine in single cord blood transplantation for elderly patients with non-remission myeloid malignancies
Allogeneic hematopoietic cell transplantation (HCT) is the only potential curative therapy for patients with non-remission myeloid malignancies [1-3]. Cord blood transplantation (CBT) is an acceptable alternative donor source for patients without human leukocyte antigen (HLA)-matched related or unrelated donors in need of allogeneic HCT [4-9]. Owing to its rapid availability, CBT can enable patients with non-remission myeloid malignancies to perform allogeneic HCT at the optimal time. In addition, because recipient and donor ages are usually similar and the prevalence of various comorbidities increases with age, it is diff...
Source: Biology of Blood and Marrow Transplantation - December 7, 2018 Category: Hematology Authors: Takaaki Konuma, Seiko Kato, Masamichi Isobe, Mai Mizusawa, Maki Oiwa-Monna, Satoshi Takahashi, Arinobu Tojo Source Type: research

Pulmonary impairment following respiratory viral infections is associated with high mortality in allogeneic hematopoietic cell transplant recipients
Hematopoietic cell transplantation (HCT) is an important curative option for many refractory and high-risk malignancies [1]. Respiratory viral infections (RVIs) are increasingly recognized as important causes of morbidity and mortality in the general population [2], and are particularly common after HCT [3,4]. Depending on the viral species, more than 30% of RVIs in HCT recipients progress to lower respiratory tract infections (LRIs) [3], resulting in high mortality [5-9]. About 30% of allogeneic HCT (allo-HCT) recipients develop LRI after respiratory syncytial virus (RSV) infection, and the overall mortality rate after RS...
Source: Biology of Blood and Marrow Transplantation - December 3, 2018 Category: Hematology Authors: Ajay Sheshadri, Roy F. Chemaly, Amin M. Alousi, Pankil K. Shah, Gabriela Rondon, Lara Bashoura, Joumana Kmeid, Jacques Azzi, David W. Blanco, Maryam Kaous, Burton F. Dickey, Richard E. Champlin, Dimpy P. Shah Source Type: research

Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT
Hematopoietic cell transplantation (HCT) is a curative treatment for many hematologic malignancies and nonmalignant disorders, although a variety of complications and late effects may occur.[1-3] Non-graft-versus-host disease (non-GVHD) ocular complications are generally uncommon after HCT, but can cause prolonged morbidity affecting activities of daily living and quality of life. It is important for all health professionals taking care of HCT recipients to have adequate knowledge about ocular complications. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - December 3, 2018 Category: Hematology Authors: Yoshihiro Inamoto, Igor Petri ček, Linda Burns, Saurabh Chhabra, Zack DeFilipp, Peiman Hematti, Alicia Rovó, Raquel Schears, Ami Shah, Vaibhav Agrawal, Aisha Ahmed, Ibrahim Ahmed, Asim Ali, Mahmoud Aljurf, Hassan Alkhateeb, Amer Beitinjaneh, Neel Bhatt, Source Type: research

ASBMT Notes
In last month's issue, we covered the history of cellular transplantation, and where leaders think it will go in the next 20 years. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - December 1, 2018 Category: Hematology Tags: ASBMT Notes Source Type: research

Masthead (Purpose and Scope)
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - December 1, 2018 Category: Hematology Source Type: research

Editorial Board
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - December 1, 2018 Category: Hematology Source Type: research

Officers and Directors of ASBMT
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - December 1, 2018 Category: Hematology Source Type: research

Table of Contents
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - December 1, 2018 Category: Hematology Source Type: research

Fludarabine/melphalan 100 mg/m2 Conditioning Therapy Followed by Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis
Adult hemophagocytic lymphohistiocytosis (HLH) is a rare but fatal disease [1,2]. Furthermore, the diagnosis of HLH remains challenging, despite recent advances in diagnostic methods, including molecular testing [3,4]. The occurrence of HLH is associated with dysfunction of natural killer cells and cytotoxic T lymphocytes, which is caused in primary HLH by genetic mutations affecting the cytotoxic granule activity pathway or is caused in secondary HLH by malignancies, infections, autoimmune diseases, and medications [5,6]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 30, 2018 Category: Hematology Authors: Han-Seung Park, Jung-Hee Lee, Je-Hwan Lee, Eun-Ji Choi, Sun-Hye Ko, Miee Seol, Young-Shin Lee, Young-Ah Kang, Mijin Jeon, Kyoo-Hyung Lee Source Type: research

Flt3L treatment of bone marrow donors increases graft plasmacytoid dendritic cell content and improves allogeneic transplant outcomes
Higher numbers of donor plasmacytoid dendritic cells (pDC) increased survival and reduced graft-versus-host disease (GvHD) in human recipients of unrelated donor bone marrow (BM), but not G-CSF peripheral blood grafts. In murine models, we have shown that donor BM pDC increase survival and decrease GvHD compared to G-CSF-mobilized pDC. To increase the content of pDC in BM grafts we studied the effect of FMS-like tyrosine kinase 3 ligand (Flt3L) treatment of murine BM donors on transplant outcomes. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 29, 2018 Category: Hematology Authors: Mojibade Hassan, Alina Ulezko Antonova, Jian Ming Li, Sakura Hosoba, Manali Rupji, Jeanne Kowalski, Adam J. Perricone, David L. Jaye, Henry Marsh, Michael Yellin, Steven Devine, Edmund K. Waller Source Type: research

FLT3-ITD and CEBPA mutations predict prognosis in acute myeloid leukemia irrespective of hematopoietic stem cell transplantation
Acute myeloid leukemia (AML) is a heterogeneous disease of varying prognosis. Chromosomal aberrations are found in approximately 55% of adult patients with AML and have high prognostic significance in patient response to therapy, risk of relapse, and overall survival [1 –4]. Three cytogenetic risk groups are currently in use: favorable, intermediate, and adverse. Adverse cytogenetic risk group is largely homogenous and generally includes abnormalities of 3q (i.e. inv(3q), t(3;3), 5q/-5, 7q/-7, abn(17p), t(6;9), 11q23 [except t(9;11)] and complex karyotypes [3]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 29, 2018 Category: Hematology Authors: Hong Wang, Tian-Tian Chu, Shi-Yu Han, Jia-Qian Qi, Ya-Qiong Tang, Hui-Ying Qiu, Cheng-Cheng Fu, Xiao-Wen Tang, Chang-Geng Ruan, De-Pei Wu, Yue Han Source Type: research

Clinical and economic impact of the cytomegalovirus infection among children undergoing allogeneic hematopoietic cell transplantation
Allogeneic hematopoietic cell transplantation (alloHCT) is a curative treatment for various malignant and non-malignant diseases in children[1]. Although, human leukocyte antigen (HLA)-matched siblings are the preferred donors for most alloHCT, they are available for only 18% of patients. For the remaining patients, alternative donor sources (unrelated donors, umbilical cord blood, or partially matched family donors) are utilized[2,3]. For alternative donors, some centers administer serotherapy such as ATG or Alemtuzumab to prevent both graft rejection and acute graft-versus-host disease (aGVHD). (Source: Biology of Blood ...
Source: Biology of Blood and Marrow Transplantation - November 28, 2018 Category: Hematology Authors: Sonal Rastogi, Angela Ricci, Zhezhen Jin, Monica Bhatia, Diane George, James H. Garvin, Matthew Hall, Prakash Satwani Source Type: research

Check-Point Inhibitors before and after Allogeneic Hematopoietic Stem Cell Transplant: The Double-Edge Sword
Co-inhibitory signaling pathways play a pivotal role in hampering immune responses in cancer patients, enabling tumor escape. In hematologic malignancies, allogeneic hematopoietic stem cell transplantation (allo-HSCT) was the first immunotherapy to demonstrate clinical efficacy with a potential to cure. More recently, clinical trials with antibodies targeting both the PD-1 and CTLA-4 pathways demonstrated efficacy, with durable remissions in a proportion of patients, in a variety of solid tumors, and more recently in hematologic malignancies [1]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 27, 2018 Category: Hematology Authors: Betul Oran, Naval Daver Source Type: research

Patient-Reported Outcomes with Chimeric Antigen Receptor-T Cell Therapy: Challenges and Opportunities
The development of chimeric antigen receptor-T (CAR-T) cell therapy has revolutionized the treatment of relapsed and refractory malignancies. The Food and Drug Administration (FDA) has approved CD-19 CAR-T cell therapy for treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL) based on impressive response rates in registration studies [1,2]. Several clinical trials on CAR-T cells are currently ongoing in multiple hematologic and solid malignancies and the common toxicities associated with this therapy have been well described. (Source: Biology of Blood and Ma...
Source: Biology of Blood and Marrow Transplantation - November 27, 2018 Category: Hematology Authors: Navneet S Majhail, Rajshekhar Chakraborty, Gunjan L Shah, Betty K Hamilton, Michael Scordo, Surbhi Sidana Source Type: research

CheckPoint Inhibitors before and after Allogeneic Hematopoietic Stem Cell Transplant: The Double Edge Sword
Co-inhibitory signaling pathways play a pivotal role in hampering immune responses in cancer patients, enabling tumor escape. In hematological malignancies, allogeneic hematopoietic stem cell transplantation (allo-HSCT) was the first immunotherapy to demonstrate clinical efficacy with a potential to cure. More recently, clinical trials with antibodies targeting both the PD-1 and CTLA-4 pathways demonstrated efficacy, with durable remissions in a proportion of patients, in a variety of solid tumors, and more recently in hematologic malignancies [1]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 27, 2018 Category: Hematology Authors: Betul Oran, Naval Daver Source Type: research

Haploidentical bone marrow transplant with post-transplant cyclophosphamide plus thiotepa improves donor engraftment in patients with sickle cell anemia: results of an international learning collaborative
Sickle cell disease (SCD) has evolved from a life-threatening condition in early childhood, to a chronic disease in adults [1,2]. Improved supportive care [3], use of hydroxyurea therapy [4], and regular blood transfusion therapy for primary [5] and secondary [6] stroke prevention, have resulted in improved childhood clinical outcomes and survival. Approximately 99% of all children born in high resource countries with SCD are expected to live to adulthood [7,8]. The most feared complication in children with SCD is stroke [9]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 27, 2018 Category: Hematology Authors: Josu de la Fuente, Nathalie Dhedin, Tatsuki Koyama, Francoise Bernaudin, Mathieu Kuentz, Leena Karnik, G érard Socié, Kathryn A. Culos, Robert A. Brodsky, Michael R. DeBaun, Adetola A. Kassim Source Type: research

Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources
Allogeneic hematopoietic cell transplantation (HCT) is a curative therapeutic modality for most malignant and non-malignant hematological disorders. However, this treatment could be associated with a substantial risk of subsequent non-relapse mortality (NRM). Pre-transplant comorbidities, as evaluated by the hematopoietic cell transplantation-specific comorbidity index (HCT-CI), have been shown to provide accurate estimates about post allogeneic HCT NRM [1]. The prognostic value of the HCT-CI was further augmented by the addition of a score of 1 for ages ≥40 years [2] and scores for values of serum levels of ferritin, a...
Source: Biology of Blood and Marrow Transplantation - November 27, 2018 Category: Hematology Authors: Mahmoud Elsawy, Barry E. Storer, Filippo Milano, Brenda M. Sandmaier, Colleen Delaney, Rachel B. Salit, Ahmed H. Rashad, Ann E. Woolfrey, Frederick R. Appelbaum, Rainer Storb, Mohamed L. Sorror Source Type: research

Occurrence and Severity of DLI associated Chronic GVHD Influence the Clinical Outcomes in Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
Allogeneic hematopoietic stem cell transplantation (HSCT) is the most effective treatment for acute leukemia. However, post-transplantation relapse remains one of the most important causes of transplant failure. Donor lymphocyte infusion (DLI), which aims to induce a graft-versus-leukemia (GVL) effect, is the most important immunotherapy for relapse after HSCT [1 –4]. We also reported that chemotherapy plus DLI (Chemo-DLI) can significantly improve the outcomes of patients who relapsed after allo-HSCT compared with those received chemotherapy alone [5,6]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 25, 2018 Category: Hematology Authors: Wen-Jing Yu, Xiao-Dong Mo, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Kai-Yan Liu, Xiao-Jun Huang Source Type: research

Cytomegalovirus (CMV) infection in allogeneic HCT managed by the preemptive approach: Estimating the impact on health care resource utilization and outcomes
Cytomegalovirus (CMV) viremia occurs in 40-90% of CMV seropositive recipients (R+) [1-3] and is associated with increased overall mortality after HCT [4]. Risk factors for CMV reactivation after HCT are well established and include T-cell depletion, allograft from HLA mismatched or CMV-seronegative donor (D −) and graft versus host disease (GVHD) [1,4]. Preemptive therapy (PET) has reduced the rates of CMV end-organ disease to less than 5% [5] the trade-off being increased use of CMV antivirals with their associated toxicities and potentially prolonged hospital length of stay (LOS). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 24, 2018 Category: Hematology Authors: Yao-Ting Huang, Yiqi Su, Seong Jin Kim, Paige Nichols, Daniel Burack, Molly Maloy, Sergio Giralt, Miguel-Angel Perales, Ann A. Jakubowski, Genovefa A. Papanicolaou Source Type: research

Peripheral Immunotype Correlates with Minimal Residual Disease Status and is Modulated by Immunomodulatory Drugs (IMiDs) in Multiple Myeloma
The immune system plays an essential role in both promoting and inhibiting growth of multiple myeloma. Besides oncogenic events intrinsic to plasma cells, numerous immune mechanisms play role in disease progression, including down regulation of NK cytotoxicity receptors (NKp30, NKp46, NKG2D),[1] expression of T cell immune checkpoint receptors (PD1, Tim3), [2, 3] and activation/expansion of immune suppressive cell types.[4, 5] Furthermore, immune contexture tends to change in response to treatment. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 24, 2018 Category: Hematology Authors: Manisha Bhutani, David Foureau, Qing Zhang, Myra Robinson, Adina S Wynn, Nury M Steuerwald, Lawrence J Druhan, Fei Guo, Katherine Rigby, Mitchell Turner, Daniel Slaughter, Reed Friend, Shebli Atrash, James T Symanowski, Belinda R Avalos, Edward A Copelan, Source Type: research

Reduction in Mortality after Umbilical Cord Blood Transplantation in Children over a 20-Year Period (1995-2014)
Allogeneic hematopoietic stem cell transplantation is used to treat a growing number of malignant and non-malignant conditions in children. When available, bone marrow from a human leukocyte antigen (HLA)-matched sibling is the preferred donor source for allogeneic stem cell transplantation. However, less than 40% of children requiring a stem cell transplant have a matched sibling donor [1]. Banked unrelated donor umbilical cord blood has been utilized for the past 25 years as an alternative donor for patients lacking a matched sibling or matched unrelated adult donor [2]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 24, 2018 Category: Hematology Authors: Lisa Spees, Paul L. Martin, Joanne Kurtzberg, Andre Stokhuyzen, Lauren McGill, Vinod K. Prasad, Timothy A. Driscoll, Suhag H. Parikh, Kristin M. Page, Richard Vinesett, Christopher Severyn, Anthony D. Sung, Alan D. Proia, Kirsten Jenkins, Mehreen Arshad, Source Type: research

A 4 or 5 Deauville score assessed by (18)F-FDG-PET CT early post-allotransplant is highly predictive of relapse in lymphoma patients
The impact of early Fluorine-18 Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET-CT) status on survival after allogeneic transplantation for lymphoma is poorly reported.This retrospective study included all adult Hodgkin (HL) or non-Hodgkin (NHL) lymphoma patients (>18 years old) who benefited from FDG PET-CT before (within 1 month) and/or early (+3 months and within +6-9 months) after Allo-SCT in our institution between 2005 and 2015 and who were still without documented progression nor relapse at the time of the FDG PET-CT. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 24, 2018 Category: Hematology Authors: L. Bouard, C. Bodet-Milin, C. Bailly, T. Guillaume, P. Peterlin, A. Garnier, A. Le Bourgeois, B. Mah é, V. Dubruille, N. Blin, C. Touzeau, T. Gastinne, A. Lok, A. Bonnet, Marie C Béné, S. Le Gouill, P. Moreau, F. Kraeber-Bodéré, P. Chevallier Tags: Original Article Source Type: research

Effects of low-dose glucocorticoid prophylaxis on chronic GVHD and GVHD-free, relapse-free survival after haploidentical transplantation: long-term follow-up of a controlled, randomized open-label trial
Allogeneic stem cell transplantation (allo-SCT) is limited by the major lethal complication of acute and/or chronic graft-versus-host disease (GVHD) [1-4]. Corticosteroids are an accepted primary therapy for both acute and chronic GVHD [5,6], which have also been successfully used for prophylaxis of acute GVHD [7-9]. Randomized studies have demonstrated that the addition of corticosteroids resulted in a statistically significant reduction of the cumulative incidence of grades II-IV acute GVHD [7,9-11]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 24, 2018 Category: Hematology Authors: Ying-Jun Chang, Lan-Ping Xu, Yu Wang, Xiao-Hui Zhang, Huan Chen, Yu-Hong Chen, Feng-Rong Wang, Wei Han, Yu-Qian Sun, Chen-Han Yan, Fei-Fei Tang, Xiao-Dong Mo, Kai-Yan Liu, Xiao-Jun Huang Source Type: research

Ocular graft-versus-host disease after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT
Allogeneic hematopoietic cell transplantation (HCT) is a curative treatment for many hematologic malignancies and nonmalignant disorders. Chronic graft-versus-host disease (GVHD) is a leading cause of late morbidity and mortality in transplant survivors, compromising both quality of life (QOL) and function [1]. Ocular involvement is common in patients with chronic GVHD, occurring in more than fifty percent [2-5]. Since the ocular surface can be evaluated by physicians and ophthalmologists, it is important for all health professionals taking care of HCT recipients to have adequate knowledge of ocular GVHD. (Source: Biology ...
Source: Biology of Blood and Marrow Transplantation - November 24, 2018 Category: Hematology Authors: Yoshihiro Inamoto, Nuria Vald és-Sanz, Yoko Ogawa, Monica Alves, Luigi Berchicci, John Galvin, Hildegard Greinix, Gregory A. Hale, Biljana Horn, Debra Kelly, Hien Liu, Scott Rowley, Helene Schoemans, Ami Shah, Maria Teresa Lupo Stanghellini, Vaibhav Agra Source Type: research

Fluoroquinolone prophylaxis is highly effective for the prevention of central line-associated bloodstream infections in autologous stem cell transplant patients
Over the past decade, rates of central line-associated bloodstream infections (CLABSIs) have been reduced by over 50% among hospitalized patients through the implementation of standardized infection prevention strategies. [1,2] However, CLABSIs remain common in patients with hematologic malignancy and are associated with significant morbidity and mortality, including an increased risk of acute graft-versus host disease (GVHD), prolonged lengths of stay, and up to a 7-fold increased risk of death. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 24, 2018 Category: Hematology Authors: Matthew Ziegler, Daniel Landsburg, David Pegues, Warren Bilker, Cheryl Gilmar, Colleen Kucharczuk, Theresa Gorman, Kristen Bink, Amy Moore, Rebecca Fitzpatrick, Edward A. Stadtmauer, Patricia Mangan, Kelly Kraus, Jennifer H. Han Source Type: research

Addendum to: Haploidentical Related Donor Hematopoietic Stem Cell Transplantation for DOCK8 Deficiency Using Post-Transplantation Cyclophosphamide
The authors wish to add back an eighth patient, the sixth transplant recipient in the study, who was underwent contemporaneous hematopoietic stem cell transplantation (HSCT) during the same period. This patient received a tandem living donor liver and bone marrow transplant, with both organs procured from the same haploidentical related maternal donor. Due to complications of veno-occlusive disease, acyclovir-resistant herpes simplex virus, and graft failure, this patient did not survive HSCT. This case was omitted because it is sufficiently different from the others but will be reported separately to fully discuss importa...
Source: Biology of Blood and Marrow Transplantation - November 22, 2018 Category: Hematology Authors: Nirali N. Shah, Dennis D. Hickstein Source Type: research

The Optimal Killer Cell Immunoglobulin-Like Receptor Donor —We Can Recognize, but Can We Search?
The role of natural killer (NK) cells in relapse protection after hematopoietic cell transplantation (HCT) for patients with acute myelogenous leukemia (AML) is well recognized and has been extensively studied using various models of NK cell alloreactivity [1]. Among numerous NK cell receptors, the most extensively studied are the killer cell immunoglobulin-like receptors (KIRs), which can be either inhibitory or activating. The binding of inhibitory KIRs to their ligands (major histocompatibility complex class I molecules) protects the cell from NK cell cytotoxicity. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 22, 2018 Category: Hematology Authors: Rohtesh S. Mehta, Betul Oran Source Type: research

The optimal kir donor – we can recognize, but can we search?
The role of natural killer (NK) cells in relapse protection after hematopoietic cell transplantation (HCT) for patients with acute myeloid leukemia (AML) is well recognized and has been extensively studied using various models of NK cell alloreactivity [1]. Among numerous NK cell receptors, the most extensively studied are the Killer-cell immunoglobulin-like receptors (KIRs), which can be either inhibitory or activating. The binding of inhibitory KIRs to their ligands (histocompatibility complex (MHC) class I molecules) protects the cell from NK cell cytotoxicity. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 22, 2018 Category: Hematology Authors: Rohtesh S. Mehta, Betul Oran Source Type: research

ERRATUM: Haploidentical Related Donor Hematopoietic Stem Cell Transplantation for DOCK8 Deficiency Using Post-Transplantation Cyclophosphamide
Erratum Text: The authors wish to add-back an eighth patient, sixth transplanted  in the study, who was contemporaneously transplanted during the same period. This patient received a tandem living donor liver and bone marrow transplant, with both organs procured from the same haploidentical related maternal donor. Due to complications of veno-occlusive disease, acyclovir-resis tant HSV and graft failure, this patient did not survive her transplant. This case was omitted because it is sufficiently different from the others, but will be reported separately to fully discuss important implications when consideri...
Source: Biology of Blood and Marrow Transplantation - November 22, 2018 Category: Hematology Authors: Nirali N. Shah, Dennis D. Hickstein Source Type: research

Choosing a Reduced Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation, Fludarabine Busulfan versus Fludarabine Melphalan: A Systematic Review and Meta-analysis
Allogeneic hematopoietic stem cell transplantation (HCT) has evolved as a potential curative therapy for various hematological malignancies [1, 2]. Regimen-related toxicity and transplant-related mortality preclude the use of conventional myeloablative conditioning (MAC) regimens in patients who are older or have a poorer functional status. Reduced intensity conditioning (RIC) regimens have extended the use of HCT in older and less fit patients, who are not able to tolerate MAC regimens with HCT. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 21, 2018 Category: Hematology Authors: Tania Jain, Fares Alahdab, Belal Firwana, Mohamad Bassam Sonbol, Diana Almader-Douglas, Jeanne Palmer Source Type: research

Etanercept as treatment of steroid-refractory acute graft versus host disease in pediatric patients
Allogeneic hematopoietic stem cell transplantation (HSCT) is an established and potentially curative treatment for a variety of malignant and non-malignant diseases. Graft versus Host Disease (GvHD) represents the main complication following HSCT. The introduction of anti-thymocyte globulin (ATG) as GvHD prophylaxis and of new therapies (e.g. mycophenolate mofetil, budesonide or extracorporeal photophoresis) as GvHD treatment has improved the prognosis of this transplant-related complication, but cases of refractory GvHD still occur. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 21, 2018 Category: Hematology Authors: Maura Faraci, Maria Grazia Calevo, Stefano Giardino, Massimiliano Leoni, Erica Ricci, Elio Castagnola, Edoardo Lanino Source Type: research

Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory GI Acute GvHD: A Retrospective Record Review
Allogeneic hematopoietic cell transplantation (allo-HCT) can be curative in patients with hematological malignancies or benign hematological conditions, but its success is limited by the development of acute and chronic graft-versus-host disease (GvHD) [1,2]. Most commonly, acute GvHD (aGvHD) involves the skin, liver, and gastrointestinal (GI) tract [3,4]. Acute GvHD of Grades II –IV and Grades III–IV have been reported in 39–71% and 14–32% of allo-HCT recipients, respectively, despite standard methods of GvHD prophylaxis [5,6]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 20, 2018 Category: Hematology Authors: Yngvar Fl øisand, Vladimir Lj Lazarevic, Johan Maertens, Jonas Mattsson, Nirav N. Shah, Pierre Zachée, Aliki Taylor, Mona Akbari, Syed Quadri, Andrejus Parfionovas, YiBin Chen Source Type: research

Impact of Empiric Treatment for Vancomycin-Resistant Enterococcus in Colonized Patients Early after Allogeneic Hematopoietic Stem Cell Transplantation
Vancomycin-resistant Enterococcus (VRE) is now a common problem among allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients and is the leading cause of nosocomial bloodstream infections (BSIs) at some centers, especially in the early post-transplantation period [1,2]. Gastrointestinal colonization with VRE is a strong predictor of BSIs in this population [3 –5]. The progression to VRE bacteremia (VREB) early post-transplantation has been reported to occur in 11% to 34% of VRE-colonized patients [4–7]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 15, 2018 Category: Hematology Authors: Mini Kamboj, Nina Cohen, Yao-Ting Huang, Marina Kerpelev, Ann Jakubowski, Kent A. Sepkowitz, Genovefa A. Papanicolaou, Susan K. Seo Source Type: research

Impact of empiric treatment for vancomycin-resistant Enterococcus (VRE) in colonized patients early after allogeneic hematopoietic stem cell transplantation
Vancomycin-resistant Enterococcus (VRE) is now a common problem among allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients and is the leading cause of nosocomial bloodstream infections (BSI) at some centers, especially in the early post-transplant period [1, 2]. Gastrointestinal colonization with VRE is a strong predictor of BSI in this population [3-5]. The progression to VRE bacteremia (VREB) early post-transplant has been reported to occur in 11-34% of VRE-colonized patients [4-7]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 15, 2018 Category: Hematology Authors: Mini Kamboj, Nina Cohen, Yao-Ting Huang, Marina Kerpelev, Ann Jakubowski, Kent A. Sepkowitz, Genovefa A. Papanicolaou, Susan K. Seo Source Type: research

The Future of Chimeric Antigen Receptor T Cell Therapy for the Treatment of Multiple Myeloma
On June 29, 2007 the first iPhone was released in the US and there was a feeling it would be an extraordinary, life changing product. It revolutionized how we interact with phones, more specifically smartphones, which now serve as an extension of our lives to what essentially amounts to an obligate symbiotic relationship. This product, called the iPhone 2G, was only the first iteration of many subsequent generations of iPhones. However, it came at a hefty price at $599 for the 8GB model. The development of chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma (MM) and other malignancies is, in many ways, anal...
Source: Biology of Blood and Marrow Transplantation - November 15, 2018 Category: Hematology Authors: R Frank Cornell, Luciano J Costa Source Type: research

Comprehensive B Cell Phenotyping Profile for Chronic Graft-Versus-Host Disease Diagnosis
Chronic graft-versus-host disease (cGvHD) is now the leading cause of late non-relapse mortality and morbidity following allogeneic hematopoietic cell transplantation (HCT) [1]. The pathogenic role of B cells in cGvHD was first identified in murine models in 1995 [2]. The role of abnormalities in B cell function have been confirmed in humans due to the successful use of B cell directed therapies such as rituximab [3] and approval of the first FDA approved drug for cGvHD therapy, ibrutinib [4]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 14, 2018 Category: Hematology Authors: Jacob Rozmus, Amina Kariminia, Sayeh Abdossamadi, Barry E. Storer, Paul J. Martin, Stephanie J. Lee, Daniel Wolff, Mukta Arora, Corey Cutler, Kirk R. Schultz Source Type: research

Microbes and Their Metabolites Correlate with Hematopoietic Stem Cell Transplantation Outcomes?
The process of allogeneic (allo-) hematopoietic stem cell transplantation (HSCT) causes loss of diversity and alters the composition of intestinal microbiota by antibiotic treatment and the development of acute graft-versus-host disease (aGVHD) [1]. Conversely, intestinal microbiota has been shown to modulate post –allo-HSCT outcomes including severity and mortality from aGVHD, bloodstream infections, overall survival, and relapse [2–5]. The mechanisms underpinning these effects on allo-HSCT clinical outcomes could involve alterations in the quality and quantity of microbial metabolites such as short-chai n fat...
Source: Biology of Blood and Marrow Transplantation - November 12, 2018 Category: Hematology Authors: Mary Riwes, Pavan Reddy Source Type: research

Microbes and their metabolites correlate with HSCT outcomes?
The process of allogeneic (allo) hematopoietic stem cell transplantation (HSCT) causes loss of diversity and alters the composition of the intestinal microbiota by antibiotic treatment and the development of acute graft versus host disease (aGVHD)[1]. Conversely, the intestinal microbiota has been shown to modulate post allo HSCT outcomes including severity and mortality from aGVHD, bloodstream infections, overall survival, and relapse [2-5]. The mechanisms underpinning these effects on allo HSCT clinical outcomes could involve alterations in the quality and quantity of microbial metabolites such as short chain fatty acids...
Source: Biology of Blood and Marrow Transplantation - November 12, 2018 Category: Hematology Authors: Mary Riwes, Pavan Reddy Source Type: research

Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study
Over the past decade registries such as the National Marrow Donor Program (NMDP) have published detailed data describing the unrelated donor (URD) experience, identifying individuals at increased risk for pain and collection-related symptoms, slower recovery, need for placement of a central venous line (CVL), and severe adverse events [1 –6]. In spite of the fact that roughly half of allogeneic hematopoietic cell donations come from related donors (RDs), data describing details of early toxicities and longer-term outcomes in these individuals are scarce, with only 1 large study focusing mainly on severe adverse event...
Source: Biology of Blood and Marrow Transplantation - November 10, 2018 Category: Hematology Authors: Michael A. Pulsipher, Brent R. Logan, Pintip Chitphakdithai, Deidre M. Kiefer, Marcie L. Riches, J. Douglas Rizzo, Paolo Anderlini, Susan F. Leitman, James W. Varni, Hati Kobusingye, RaeAnne M. Besser, John P. Miller, Rebecca J. Drexler, Aly Abdel-Mageed, Source Type: research

Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation
Obesity incidence has been increasing steadily in recent years [1 –3]. The American Society of Clinical Oncology guidelines recommended chemotherapy dosing based on actual body weight (ABW) for obese patients treated with curative-intent [4] chemotherapy in solid tumors. In contrast, hematopoietic cell transplantation (HCT) requires higher doses of chemotherapy, and practices of adjusting the weight because of concerns of organ toxicity are common [5,6]. In 2014 the American Society for Blood and Marrow Transplant completed an extensive review of the literature and published recommendations on chemotherapy dosing in ...
Source: Biology of Blood and Marrow Transplantation - November 10, 2018 Category: Hematology Authors: Claudio G. Brunstein, Marcelo C. Pasquini, Soyoung Kim, Mingwei Fei, Kehinde Adekola, Ibrahim Ahmed, Mahmoud Aljurf, Vaibhav Agrawal, Jeffrey J. Auletta, Minoo Battiwalla, Nelli Bejanyan, Joseph Bubalo, Jan Cerny, Lynette Chee, Stefan O. Ciurea, Cesar Fre Source Type: research

Clinical implications of t(11;14) in patients with multiple myeloma undergoing autologous stem cell transplantation
Multiple myeloma (MM) with t(11;14) is classified into the standard-risk category according to the International Myeloma Working Group (IMWG) and Mayo Clinic criteria [1,2]. However, recent reports have shown that the prognosis for MM with t(11;14) falls between that for MM without t(11;14)/t(4;14)/t(14;16)/del 17p and MM with t(4;14)/t(14;16)/del 17p [3,4]. Furthermore, additional chromosomal abnormalities (ACAs) detected by G-banding, except for nonhypodiploid and del(13) [5], are excluded from the IMWG and Mayo Clinic criteria, and many hospitals in the USA no longer perform cytogenetic analyses to evaluate the metaphas...
Source: Biology of Blood and Marrow Transplantation - November 10, 2018 Category: Hematology Authors: Hiroyuki Takamatsu, Takeshi Yamashita, Shingo Kurahashi, Takayuki Saitoh, Tadakazu Kondo, Takeshi Maeda, Hideyuki Nakazawa, Makoto Murata, Tomoko Narita, Junya Kuroda, Hisako Hashimoto, Koji Kawamura, Toshihiro Miyamoto, Sumihisa Honda, Tatsuo Ichinohe, Y Source Type: research

The Effect of Aging and Pre-Donation Comorbidities on the Related PBSC Donor Experience: A Report from the Related Donor Safety Study (RDSafe)
Over the past decade, registries such as the National Marrow Donor Program (NMDP) have published detailed data describing the unrelated donor (URD) experience, identifying individuals at increased risk for pain and collection related symptoms, slower recovery, need for placement of a central venous line (CVL), and severe adverse events.1-6 In spite of the fact that roughly half of allogeneic hematopoietic cell (HSC) donations come from related donors (RD), data describing details of early toxicities and longer-term outcomes in these individuals are scarce, with only one large recent study that focused mainly on severe adve...
Source: Biology of Blood and Marrow Transplantation - November 10, 2018 Category: Hematology Authors: Michael A. Pulsipher, Brent R. Logan, Pintip Chitphakdithai, Deidre M. Kiefer, Marcie L. Riches, J. Douglas Rizzo, Paolo Anderlini, Susan F. Leitman, James W. Varni, Hati Kobusingye, RaeAnne M. Besser, John P. Miller, Rebecca J. Drexler, Aly Abdel-Mageed, Source Type: research

nThe Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation
Obesity incidence has been increasing steadily in recent years [1-3]. The American Society of Clinical Oncology guidelines recommended chemotherapy dosing based on actual body weight for obese patients being treated with curative-intent [4] chemotherapy in solid tumors. In contrast, hematopoietic cell transplantation (HCT) requires higher doses of chemotherapy and practices of adjusting the weight due to concerns of organ toxicity are common [5, 6]. Recently, the American Society for Blood and Marrow Transplant (ASBMT) completed an extensive review of the literature and published recommendations on chemotherapy dosing in o...
Source: Biology of Blood and Marrow Transplantation - November 10, 2018 Category: Hematology Authors: Claudio G. Brunstein, Marcelo C. Pasquini, Soyoung Kim, Mingwei Fei, Kehinde Adekola, Ibrahim Ahmed, Mahmoud Aljurf, Vaibhav Agrawal, Jeffrey J. Auletta, Minoo Battiwalla, Nelli Bejanyan, Joseph Bubalo, Jan Cerny, Lynette Chee, Stefan O. Ciurea, Cesar Fre Source Type: research

Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes
Patients with relapsed or refractory acute myelogenous leukemia (AML) have limited treatment options and a generally poor prognosis. The outcomes after allogeneic hematopoietic stem cell transplantation (HSCT) are poor in such patients [1 –4]. Additional medical interventions to induce remission have been exhausted in most cases. Adoptive cell therapy using donor cells from partially matched related donors has been used to induce an antileukemic effect without durable engraftment [5]. Guo et al [6,7] reported this approach for trea tment of older patients with AML with encouraging response rates. (Source: Biology of ...
Source: Biology of Blood and Marrow Transplantation - November 8, 2018 Category: Hematology Authors: Usama Gergis, Emeline Masson Frenet, Tsiporah Shore, Sebastian Mayer, Adrienne Phillips, Jing-Mei Hsu, Gail Roboz, Ellen Ritchie, Joseph Scandura, Sangmin Lee, Pinkal Desai, Michael Samuel, Jeffrey Ball, Anthony Blanco, Cynthia Romeo, Maria S Albano, Ludy Source Type: research